Posted by Michael Wonder on 30 Apr 2025
Johnson & Johnson receives FDA approval for Imaavy (nipocalimab-aahu), a new FcRn blocker offering long-lasting disease control in the broadest population of people living with generalized myasthenia gravis
30 April 2025 - First and only FcRn blocker approved in anti-AChR and anti-MuSK antibody positive adults and paediatric generalised myasthenia gravis. patients aged 12 and older.
Johnson & Johnson today announced that the US FDA has approved Imaavy (nipocalimab-aahu), a human FcRn-blocking monoclonal antibody for the treatment of generalised myasthenia gravis.
